Compare Adaptive Biotechnologies Corp (ADPT) vs Cintas Corporation (CTAS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Cintas Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while Cintas Corporation trades at $205.78 (market cap $82.15B). The key difference: Cintas Corporation is far larger — about 20.3× Adaptive Biotechnologies Corp's market cap, and Cintas Corporation pays a 1.01% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | CTAS | |
|---|---|---|
Market Cap | $4.04B | $82.15B |
Sector | Health | Industrials |
52-Week High | $25.45 | $225.10 |
52-Week Low | $12.30 | $163.55 |
Enterprise Value | $4.10B | $84.56B |
Dividend Yield | — | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
Cintas (CTAS) trades at $203.51, up 0.39% on the day, with a bullish technical signal and recent earnings beats driving momentum. The company reported strong fiscal 2026 results with revenue of $10.34 billion and net income of $1.81 billion, supported by robust profitability margins. Analyst consensus is a 'Buy' with a $225.83 price target, though valuation multiples like a P/E of 41.81 suggest premium pricing. Recent news highlights dividend declarations and institutional buying interest.
Outlook remains positive given consistent earnings outperformance and upward revenue guidance, but risks include high valuation sensitivity and economic cyclicality. The stock offers growth potential from operational efficiency and market share gains, yet investors should weigh elevated multiples against sector peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →
